ROIV - Roivant Sciences founder Ramaswamy considering 2024 presidential run - POLITICO

Vivek Ramaswamy, the founder and former CEO of Roivant Sciences ( NASDAQ: ROIV ), is considering a bid for the Republican presidential nomination, POLITICO reported.

The political news website said that the former exec, who is also known for launching several other "vant" companies, spoke at a dinner last month featuring the Iowa's agricultural elites. He has made other appearances in the state .

Ramaswamy is also co-founder and executive chairman of Strive Asset Management.

Ramaswamy left his job as Roivant ( ROIV ) CEO in 2021. Under his leadership, the company launched five subsidiaries: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences. In 2019, Sumitomo Pharma ( OTCPK:DNPUF ) eventually acquired Roivant's ( ROIV ) stakes in some of the subsidiaries for $3B.

In October 2022, Sumitomo agreed to purchase Myovant Sciences ( MYOV ) for ~$1.7B and take the company private .

So far, former President Donald Trump is the only candidate to formally acknowledge a 2024 presidential run, though Florida Gov. Ron DeSantis and Texas Sen. Ted Cruz are among the other candidates reportedly mulling throwing their hats in.

Ramaswamy may be more familiar to Republican voters as the author of Woke, Inc.: Inside Corporate America's Social Justice Scam, which was No. 2 on The New York Times Best Sellers List when first released in 2021.

Roivant ( ROIV ) released its fiscal 2023 Q3 financial results Monday morning where it beat on the top but missed on the bottom line .

For further details see: